Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Revenue From Contracts With Customers (Tables)

v3.19.3
Note 3 - Revenue From Contracts With Customers (Tables)
 9 Months Ended
Sep. 30, 2019
Notes Tables  
Disaggregation of Revenue [Table Text Block]
T
hree Months Ended
September
30
, 2019
  
Diagnostics
  
Royalty revenue:
        
Europe
   $
4,895
  
T
hree Months Ended
September
30
, 2018
  
Diagnostics
  
Royalty revenue:
        
Europe
   $
2,382
  
         
License revenue:
        
NAV4694 sublicense
   $
14,930
  
Tc99m tilmanocept sublicense, China
    
5,000
  
Total
   $
19,930
  
Nine Months Ended September 30, 2019
  
Diagnostics
  
Royalty revenue:
        
Europe
   $
13,985
  
         
License revenue:
        
NAV4694 sublicense
   $
9,953
  
         
Other revenue:
        
Additional stability studies
   $
11,024
  
Nine Months Ended September
30
, 201
8
  
Diagnostics
  
Royalty revenue:
        
Europe
   $
9,842
  
         
License revenue:
        
NAV4694 sublicense
   $
272,639
  
Tc99m tilmanocept sublicense, China
    
5,000
  
Total
   $
277,639
  
         
Other revenue:
        
Additional stability studies
   $
15,037
  
Contract with Customer, Asset and Liability [Table Text Block]
   
Three Months Ended
September
30,
    
Nine
Months Ended
September
30,
  
   
2019
    
2018
    
2019
    
2018
  
Total deferred revenue, beginning of period
   $
1,195,000
     $
721,024
     $
711,024
     $
26,061
  
Impact of adoption of ASU 2014-09 and related standards
    
—
      
—
      
—
      
700,000
  
Revenue deferred related to sublicense
    
—
      
—
      
495,000
      
10,000
  
Refund of deferred revenue related to sublicense
    
(495,000
)
    
—
      
(495,000
)
    
—
  
Revenue recognized from satisfaction of performance obligations
    
—
      
(5,000
)
    
(11,024
)
    
(20,037
)
Total deferred revenue, end of period
   $
700,000
     $
716,024
     $
700,000
     $
716,024